Abstract:Activation of the stimulator of interferon genes (STING) pathway through cyclic dinucleotides (CDNs) is being explored as potent vaccine adjuvants against infectious diseases and to increase tumor immunogenicity toward cancer immunotherapy. To date, a myriad of synthetic vehicles, including liposomes, polymers, and other nanoparticle platforms, have been developed to improve the bioavailability and therapeutic efficacy of STING agonists in preclinical mouse models. Compared to synthetic materials, protein‐based carriers represent an attractive delivery platform owing to their biocompatibility, amenability to genetic engineering, and intrinsic capacity to form well‐defined structures. Here, the immune adaptor STING is engineered as aprotein‐based delivery system for efficient encapsulation and intracellular delivery of CDNs. Through genetic fusion with a protein transduction domain, the recombinant STING can spontaneously penetrate cells to markedly enhance the delivery of CDNs in a mouse vaccination model and a syngeneic melanoma model. As certain tumor cells can evade immune surveillance via loss of STING expression, authors further unveiled that the STING platform can serve as a functional vehicle to restore the STING signaling in cell lines with impaired STING expression. Altogether, their delivery platform may offer a unique direction toward targeting STING‐silenced tumors and augmenting the efficacy of STING‐based vaccine adjuvants. Protein‐based carriers are potent delivery platforms owing to their biocompatibility, amenability to genetic engineering, and intrinsic capacity to form well‐defined structures. Through engineering the stimulator of interferon genes (STING) as a protein‐based delivery system, this study provides a unique direction toward targeting STING‐deficient tumors as well as augmenting the efficacy of STING‐based vaccine adjuvants.

STING-activating drug delivery systems: Design strategies and biomedical applications

STING, a promising target for small molecular immune modulator: A review

Clinical applications of STING agonists in cancer immunotherapy: current progress and future prospects

Delivery of STING agonists for cancer immunotherapy

A next-generation STING agonist MSA-2: From mechanism to application

STING as an emerging therapeutic target for drug discovery: Perspectives from the global patent landscape

Agonists and Inhibitors of the STING Pathway: Potential Agents for Immunotherapy

Advanced nanomaterials targeting activation of STING for enhanced cancer immunotherapy

Engineering the Immune Adaptor Protein STING as a Biologic

Engineering the Immune Adaptor Protein STING as a Functional Carrier

Design and syntheses of a bimolecular STING agonist based on the covalent STING antagonist

Development of small molecule inhibitors/agonists targeting STING for disease

Structure−Activity Relationship Study of Benzothiophene Oxobutanoic Acid Analogues Leading to Novel Stimulator of Interferon Gene (STING) Agonists

Cell-to-cell communications of cGAS-STING pathway in tumor immune microenvironment.

Agonist of stimulator of interferon genes as antitumor agents: a patent review (2008-2020)

Mannosylated STING Agonist Drugamers for Dendritic Cell-Mediated Cancer Immunotherapy

Targeting STING signaling for the optimal cancer immunotherapy

Nanoparticle‐Mediated STING Activation for Cancer Immunotherapy

cGAS-STING pathway in cancer biotherapy

Novel Emerging Nano-Assisted Anti-Cancer Strategies Based on the STING Pathway

IUPHAR ECR review: The cGAS-STING pathway: Novel functions beyond innate immune and emerging therapeutic opportunities